Geriatrics News

The FDA has granted breakthrough therapy designation to gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, as an Alzheimer’s disease treatment.

Alzheimer’s disease remains a significant public health challenge, with as many as 5.8 million Americans having had the disease in 2020, according to estimates in a study published in Alzheimer’s & Dementia.

In conjunction with World Alzheimer’s Day, Healio Psychiatry has compiled a list of articles covering recent research developments related to Alzheimer’s disease.

NIH’s National Institute on Aging announced a $55.6 million grant for Alzheimer’s disease research conducted by the University of Washington, Kaiser Permanente Washington and the University of California San Diego.

When used correctly, electroconvulsive therapy can be associated with lower all-cause mortality, according to findings published in The American Journal of Psychiatry.

NIH’s National Institute on Aging announced $14.8 million in funding across 5 years for institutions in North Carolina and Texas that will join a network of research centers for Alzheimer’s disease and related dementias.

Increased expression of various X chromosome genes had different impacts on tau burden and cognition in men and women with and without Alzheimer’s disease, according to a study in JAMA Neurology.

Patients with dementia-related psychosis self-reported severe symptoms that were not reduced by current treatments, according to findings published in Clinical Gerontologist.

Inflammatory processes were linked to lower cognitive functioning in older patients with depression before electroconvulsive therapy, with further dysfunction during and after therapy, according to a Journal of Clinical Psychiatry study.

Amyloid load appeared to negatively influence the progression of self-esteem among people at risk for Alzheimer’s dementia, according to study results published in Journal of Clinical Psychiatry.